ChallenerMD Profile Banner
Greg Challener Profile
Greg Challener

@ChallenerMD

Followers
19
Following
60
Media
0
Statuses
7

Rheumatologist @mghrheumatology | formerly @MayoMN_IMRES

Boston
Joined April 2024
Don't wanna be here? Send us removal request.
@ChallenerMD
Greg Challener
9 days
Associations Between Pre‐Existing Autoimmunity and Chimeric Antigen Receptor T Cell Therapy Toxicity for Cancer Treatment - Challener - 2025 - ACR Open Rheumatology - Wiley Online Library
Tweet card summary image
acrjournals.onlinelibrary.wiley.com
Objective Chimeric antigen receptor (CAR) T cell therapy is being investigated to treat individuals with autoimmune diseases. Data regarding the safety of CAR T cell therapy in this population are...
0
0
0
@MGHrheumatology
MGH Rheumatology
4 months
0
3
3
@MGHrheumatology
MGH Rheumatology
5 months
.@MassGeneralMDs Oncorheumatology team presents abstract at #ASCO25 Clinical phenotype & management of MSK #irAEs treated with ICIs ✅️ https://t.co/SQn0A8ztgG @ChallenerMD @janethyinhmd @minnakohlermd @kreynoldsMD @ASPIRE_CoP @ASCO @MGHCancerCenter @MGH_MSUS
0
4
12
@minnakohlermd
Minna Kohler, MD, RhMSUS
1 year
Immune Checkpoint Inhibitor pts tx'd w/sulfasalazine (SSZ) ➡️ high rates of AEs/hypersensitivity rxns ➡️ SSZ discontinuation. Observed rate of AEs > in SSZ-treated RA pts @ChallenerMD @janethyinhmd @ChioYokoseMD #hyonchoimd #Oncology https://t.co/zcnof3qlGZ @sitcancer
Tweet card summary image
ard.bmj.com
Background: Sulfasalazine (SSZ) has been recommended [1] as a steroid-sparing agent for immune checkpoint inhibitor-inflammatory arthritis (ICI-IA), and this agent is sometimes favored due to its low...
0
3
8
@MGH_MSUS
MGH Rheumatology MSK Ultrasound Program
1 year
0
5
9